Soligenix gets fast track designation for RiVax

The FDA granted fast track designation to Soligenix’s (NASDAQ:SNGX) RiVax for the prevention of ricin intoxication.

Ricin is a lethal plant-derived toxin whose stability and high potency make it a potential biological weapon. RiVax is a heat-stable ricin toxin vaccine.

“We believe that the FDA’s action in granting fast track designation validates the unmet medical need that currently exists for a vaccine providing protection against lethal ricin toxin exposure and for the potential key role RiVax can serve as a part of the U.S. Strategic National Stockpile,” Christopher Schaber, Soligenix’s president and CEO, said in a statement. 

RiVax’s development of has been funded through a series of grants from the National Institute of Allergy and Infectious Diseases and the FDA.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.